Aesthetic device company Syneron Medical Ltd. (ELOS) announced Friday that it has closed the acquisition of Ultrashape Ltd., a manufacturer of non-invasive technologies for fat cell destruction and body sculpting.
The integration of Ultrashape business will begin immediately and its products will now be available through Syneron's worldwide network of direct and distributor sales channels.
Louis P. Scafuri, CEO of Syneron Medical, said, "The addition of Ultrashape's unique focused ultrasound technology will provide Syneron immediate entry into the large and attractive global market for fat cell destruction and body sculpting. Ultrashape's technology provides a differentiated, physician and patient friendly, non-invasive treatment for de-bulking and body sculpting of normal to overweight patients."
For comments and feedback: editorial@rttnews.com